• In late May 2026, Salesforce’s board declared a quarterly cash dividend of US$0.44 per share, payable on July 2, 2026 to shareholders of record on June 11, while also reporting first-quarter fiscal 2027 revenue of US$11.13 billion and net income of US$2.11 billion.
• At the same time, Salesforce expanded major AI-powered collaborations, including its largest Agentforce deal to date with CVS Health and new integrations with Cornerstone and Cint, underscoring the company’s push to make AI agents central to enterprise workflows.
• We’ll now assess how Salesforce’s US$2 billion France AI investment and accelerating Agentforce adoption may influence this investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Salesforce Investment Narrative Recap

To own Salesforce, you need to believe its pivot to AI agents and Data Cloud can offset slower legacy SaaS growth and rising competition. Right now, the key near term catalyst is whether Agentforce can keep converting pilots into large production deals, while the biggest risk is margin pressure if AI and France expansion spending outpaces revenue progress. The latest dividend, Q1 FY27 results, and AI partnership wins support the story but do not materially change those core drivers.

Among recent announcements, the expanded CVS Health collaboration stands out. It is Salesforce’s largest Agentforce deal in regulated industries and puts AI agents at the center of high stakes healthcare workflows. For investors watching whether Agentforce adoption can scale beyond early tech adopters, a deployment across Aetna and CVS Caremark offers a concrete example of Salesforce embedding AI into complex, compliance heavy operations, which directly ties back to the main growth catalyst.

Yet despite this progress, investors should still weigh how increased AI investment, integration complexity, and competition could pressure margins and growth over time...

Salesforce's narrative projects $51.9 billion revenue and $10.3 billion earnings by 2028. This requires 9.6% yearly revenue growth and an earnings increase of about $3.6 billion from $6.7 billion today.

Uncover how Salesforce's forecasts yield a $317.21 fair value, a 51% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Salesforce could reach about US$58.9 billion in revenue and US$11.6 billion in earnings, so comparing those expectations to the latest AI announcements helps you see how far views can differ and why these pre news narratives might now look either too cautious or too bold.

Explore 32 other fair value estimates on Salesforce - why the stock might be worth 6% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Salesforce research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Salesforce research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Salesforce's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.